Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen Sends Expert Researchers to US, Europe to Assess Candidate Compounds for In-licensing
November 4, 2011
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
- Complaints of Side Effects from Lyrica Up Sharply: Nextit Research
November 4, 2011
- Miraca HD: Sales, Profits Up due to Addition of Innogenetics NV
November 4, 2011
- Santen Reports Steady 5.3% Increase in Sales in Domestic, Overseas Markets in Apr-Sep
November 2, 2011
- Eisai President Says Japan, China to Become Key Battlefields for Aricept
November 2, 2011
- Bayer Yakuhin to Reorganize Structure, Offer Early Retirement Program to 150
November 2, 2011
- AstraZeneca’s 9-Month Global Sales Fell Due to Competition with Generics
November 2, 2011
- Profits Show Double-Digit Drop Due to Increased R&D Costs: Torii
November 2, 2011
- Daiichi Sankyo Suspends PII Trials in US, Europe for Post-Surgery VTE Prevention
November 2, 2011
- Shionogi Aiming for US Launch of Vaginal Atrophy Treatment Ospemifene in 2013
November 2, 2011
- Marketing of Imusera, Telavic to Be Limited to Specialists at First: MTPC
November 2, 2011
- Daiichi Sankyo Reports Decreases in Sales, Profits in Apr-Sept Term by Slump of Ranbaxy, Return of Marketing Rights
November 1, 2011
- MTPC: Profits Down but Remicade, Generics Show Steady Growth in Apr-Sept
November 1, 2011
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…